Proteolysis is a confounding factor in the interpretation of faecal calprotectin

Clinical Chemistry and Laboratory Medicine

Volumn 53, Issue 1, 2015, Pages 65-71

  Dumoulin, Els N ^a   Van Biervliet, Stephanie ^a   Langlois, Michel R ^b   Delanghe, Joris R ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Department of Pediatric Gastroenterology and Nutrition Ghent University Hospital ^*  (Belgium)

Author keywords

calprotectin; faeces; inflammatory bowel disease; proximal gut lesions; trypsin; 1< inf> antitrypsin

Indexed keywords

ALPHA 1 ANTITRYPSIN; CALGRANULIN; TRITON X 100; TRYPSIN;

ARTICLE; CELL ISOLATION; CONFOUNDING VARIABLE; CYTOLYSIS; DILUTION; ENZYME ACTIVITY; ENZYME DEGRADATION; FECES ANALYSIS; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; INCUBATION TIME; LEUKOCYTE; PROTEIN DEGRADATION; PROTEIN DEPLETION; SERUM; AMINO ACID SEQUENCE; ARTIFACT; CHEMISTRY; CLINICAL CHEMISTRY; FECES; METABOLISM; MOLECULAR GENETICS;

ALPHA 1-ANTITRYPSIN; AMINO ACID SEQUENCE; ARTIFACTS; CLINICAL CHEMISTRY TESTS; FECES; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MOLECULAR SEQUENCE DATA; PROTEOLYSIS; TRYPSIN;

EID: 84916230119     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0568     Document Type: Article

References (30)

1. Basso D, Zambon CF, Plebani M. Inflammatory bowel diseases: From pathogenesis to laboratory testing. Clin Chem Lab Med 2014;52:471-81.
2. Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir 1980;16(Suppl):273-82.
3. Poullis A, Foster R, Mendall MA, Fagerhol MK. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol 2003;18:756-62.
4. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793-8.
5. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: Diagnostic meta-Analysis. Br Med J 2010;341:c3369.
6. Van de Vijver E, Schreuder AB, Cnossen WR, Muller Kobold AC, van Rheenen PF. Safely ruling out inflammatory bowel disease in children and teenagers without referral for endoscopy. Arch Dis Child 2012;97:1014-8.
7. Sipponen T, Bjorkesten CG, Farkkila M, Nuutinen H, Savilahti E, Kolho KL. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 2010;45:325-31.
8. Sipponen T, Karkkainen P, Savilahti E, Kolho KL, Nuutinen H, Turunen U, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008;28:1221-9.
9. Keller J, Layer P. Human pancreatic exocrine response to nutrients in health and disease. Gut 2005;54(Suppl 6):vi1-28.
10. Geiger R, Fritz H. Trypsin. In: Bergmeyer HU, Bergmeyer J, Grassl M, editors. Methods of enzymatic analysis. Volume V. Enzymes 3: Peptidases, proteinases and their inhibitors, 3rd ed. Weinheim, Deerfield Beach, Florida; Basel: Verlag Chemie, 1984;119-29.
11. Smith JS, Ediss I, Mullinger MA, Bogoch A. Fecal chymotrypsin and trypsin determinations. Can Med Assoc J 1971;104:691-4.
12. Layer P, Go VL, DiMagno EP. Fate of pancreatic enzymes during small intestinal aboral transit in humans. Am J Physiol 1986;251:G475-80.
13. Layer P, Keller J. Pancreatic enzymes: Secretion and luminal nutrient digestion in health and disease. J Clin Gastroenterol 1999;28:3-10.
14. Strygler B, Nicar MJ, Santangelo WC, Porter JL, Fordtran JS. Alpha 1-Antitrypsin excretion in stool in normal subjects and in patients with gastrointestinal disorders. Gastroenterology 1990;99:1380-7.
15. Umar SB, DiBaise JK. Protein-losing enteropathy: Case illustrations and clinical review. Am J Gastroenterol 2010;105:43-9.
16. Oyaert M, Trouve C, Baert F, De Smet D, Langlois M, Vanpoucke H. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-Analytical and diagnostic performance characteristics. Clin Chem Lab Med 2014;52:391-7.
17. Fink PC, Romer M, Haeckel R, Fateh-Moghadam A, Delanghe J, Gressner AM, et al. Measurement of proteins with the Behring Nephelometer. A multicentre evaluation. J Clin Chem Clin Biochem 1989;27:261-76.
18. Kim SK. Small intestine transit time in the normal small bowel study. Am J Roentgenol Radium Ther Nucl Med 1968;104:522-4.
19. Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: A systematic review and meta-Analysis. Am J Gastroenterol 2014;109:637-45.
20. Kostakis ID, Cholidou KG, Vaiopoulos AG, Vlachos IS, Perrea D, Vaos G. Fecal calprotectin in pediatric inflammatory bowel disease: A systematic review. Dig Dis Sci 2013;58:309-19.
21. Oord T, Hornung N. Fecal calprotectin in healthy children. Scand J Clin Lab Invest 2014;74:254-8.
22. Rugtveit J, Fagerhol MK. Age-dependent variations in fecal calprotectin concentrations in children. J Pediatr Gastroenterol Nutr 2002;34:323-4.
23. Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Ruefferet A, et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007;56:1706-13.
24. Sipponen T, Haapamaki J, Savilahti E, Alfthan H, Hämäläinen E, Rautiainen H, et al. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. Scand J Gastroenterol 2012;47:778-84.
25. Fallahi G, Motamed F, Yousefi A, Shafieyoun A, Najafi M, Khodadad A, et al. The effect of probiotics on fecal calprotectin in patients with cystic fibrosis. Turk J Pediatr 2013;55:475-8.
26. Lee JM, Leach ST, Katz T, Day AS, Jaffe A, Ooi CY. Update of faecal markers of inflammation in children with cystic fibrosis. Mediators Inflamm 2012;2012:948367.
27. Bruzzese E, Raia V, Gaudiello G, Polito G, Buccigrossi V, Formicola V, et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther 2004;20:813-9.
28. Luisetti M, Seersholm N. Alpha1-Antitrypsin deficiency. 1: Epidemiology of alpha1-Antitrypsin deficiency. Thorax 2004;59:164-9.
29. Tietz NW. Section I: General clinical tests. In: Clinical guide to laboratory tests. Section I: General clinical tests, 3rd ed. Philadelphia: W.B. Saunders Company, 1995;66-7.
30. Dati F, Schumann G, Thomas L, Aguzzi F, Baudner S, Bienvenu J, et al. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP Reference Material (CRM 470). International Federation of Clinical Chemistry. Community Bureau of Reference of the Commission of the European Communities. College of American Pathologists. Eur J Clin Chem Clin Biochem 1996;34:517-20.